Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289054 · ClinicalTrials.gov registry record
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4
- Enrollment target
NCT01289054: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01289054 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01289054 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.
Interventions
- DRUG Gleevec
- DRUG Tasigna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-03 |
What the finished NCT01289054 record still lists
NCT01289054 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Gleevec is the first listed.
NCT01289054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01289054 about?
NCT01289054 is a clinical study titled "A Global Imatinib and Nilotinib Pregnancy Exposure Registry". This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.
What is the current status of trial NCT01289054?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01289054?
The interventions under investigation include: Gleevec (DRUG), Tasigna (DRUG).
Who is sponsoring clinical trial NCT01289054?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia